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Abstract
The HOGG1 gene catalyzes the excision of modified bases and removal of DNA damage adducts. It may play an important
role in the prevention of carcinogenesis. Ser
326Cys polymorphism localizes in exon 7 of the hOGG1 gene. It takes the form of
an amino acid substitution, from serine to cysteine, in codon 326. Several epidemiological association studies have been
conducted on this polymorphism and its relationship with the risk of prostate cancer. However, results have been
conflicting. To resolve this conflict, we conducted a meta-analysis on the association between this polymorphism and
prostate cancer, taking into account race, country, sources of controls, and smoking status. A total of nine studies covering
2779 cases and 3484 controls were included in the current meta-analysis. Although no significant association was found
between hOGG1 Ser
326Cys polymorphism and prostate cancer susceptibility in the pooled analysis, individuals with Ser/
Cys+Cys/Cys genotypes were found to have greater risk of prostate cancer if they were also smokers (OR=2.66, 95%
CI=1.5824.47) rather than non-smokers (OR=2.18, 95% CI=1.1324.19), compared with those with Ser/Ser genotype. In
conclusion, our meta-analysis demonstrates that hOGG1 Ser
326Cys polymorphism is a risk factor for prostate cancer in
smokers. Further studies are needed to confirm this relationship.
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Introduction
Oxidative DNA damage is involved in carcinogenesis. It causes
mutations that can inactivate tumor suppressor genes and activate
oncogenes. The major form of DNA adduction induced by
oxidative damage is 8-OH-dG (8-hydroxy-2-deoxyguanine) and
increased 8-OH-dG formation in DNA results in mutagenesis and
carcinogenesis [1]. A DNA glycosylase/apurinic-apyrimidinic
lyase encoded by the human oxoguanine glycosylase 1 (hOGG1)
gene catalyzes the excision of modified bases and removal of 8-
OH-dG adducts and has been hypothesized to play an important
role in the prevention of carcinogenesis [2].
Prostate cancer is most commonly-diagnosed malignancy in
elderly men in developed countries, and the incidence increases
every year. Deficient DNA repair mechanisms may play a role in
the age-related increase in prostate cancer risk by allowing
carcinogenic DNA damage events to accumulate uncorrected.
Higher levels of 8-OH-dG and downregulation of hOGG1 also
have been observed in benign prostatic hyperplasia (BPH) and
prostate cancer.
Variations in the hOGG1 gene have been identified and the
repair activities of the variant proteins have been evaluated in
several studies. One of the most frequently analyzed variations is in
exon 7 of the hOGG1 gene, which takes the form of a single
amino acid substitution, from serine to cysteine at codon 326
(Ser
326Cys, rs1052133). The hOGG1 protein encoded by the
Ser
326 allele showed much more DNA repair activity than that
encoded by Cys
326 allele in vitro [3]. There have also been several
epidemiological studies concerning the association between this
variation and the risk of prostate cancer. However, the results have
not been conclusive. For example, Chen et al. found that carriers
with the Cys
326 allele had a significantly increased risk of prostate
cancer, but Xu et al. found that subjects with Cys
326 allele had a
reduced risk of prostate cancer. For this reason, we conducted a
meta-analysis on hOGG1 Ser
326Cys polymorphism and the risk of
prostate cancer, taking into account certain characteristics of the
subjects and studies, such as race, country, source of controls and
smoking status. We believe that this will help us better understand
the risk of prostate cancer.
Materials and Methods
Publication search
The two online bibliographic databases (PubMed and Embase)
were consulted with the following search strategy: ‘‘human
oxoguanine glycosylase 1, hOGG1 or OGG1, hOGG or
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30309OGG,’’ ‘‘polymorphism or variant,’’ and ‘‘prostate cancer or
prostate neoplasm’’ (last search was updated on Oct. 27, 2011).
Original studies in English on hOGG1 polymorphism in prostate
cancer were included; reviews, editorials, and letters were
excluded. All the references of relevant reviews and eligible
articles that our search retrieved were checked carefully.
Inclusion criteria and data abstraction
Two investigators searched the literature and extracted data
independently. The inclusion criteria were as follows: (i) Each
study had to discuss or concern hOGG1 Ser
326Cys polymorphism
and the risk of prostate cancer. (ii) Each study had to use a case-
control design. (iii) Each study had to contain information about
available genotype frequency that could help technicians infer the
results from the papers. For each of the eligible case-control
studies, the following data were collected: the first author’s last
name, year of publication, country of origin of the subjects, race of
the subjects, sources of controls, smoking status of the subjects,
number of genotyped cases and controls, and Hardy-Weinberg
equilibrium status.
Statistical analysis
The association between hOGG1 different genotypes (including
the heterozygote comparison (Ser/Cys vs. Ser/Ser) and the
homozygote comparison (Cys/Cys vs. Ser/Ser), the dominant
genetic model (Ser/Cys+Cys/Cys vs. Ser/Ser) and the recessive
genetic model (Cys/Cys vs. Ser/Cys+Ser/Ser)) and susceptibility
to prostate cancer was measured using the crude odds ratio (OR)
with related 95% confidence interval (CI). A x
2-based Q-test was
used to check the heterogeneity of the current study and determine
the methods for calculating OR. If P.0.05 for a given Q-test
indicated a lack of heterogeneity among the studies, then the
summary ORs were calculated using the fixed-effects model (the
Mantel-Haenszel method). Otherwise, the random effects model
(DerSimonian and Laird method) was used. The significance of the
pooled OR was determined using the Z-test, and P,0.05 was
considered statistically significant. Subgroup analyses were also
conducted on the basis of subject race, country, source of controls,
and smoking status. The statistical power was calculated using PS
software (http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/
PowerSampleSize).
The publication bias was determined using Egger’s linear
regression test by visual inspection of the Funnel plot. All statistical
analyses were performed using Stata 10.0 (StataCorp LP, College
Station, TX, U.S.).
Results
Study characteristics
Characteristics of eligible studies are presented in Table 1 [4–
12]. In all, 6,968 papers were retrieved by searching for the terms
listed above (PubMed: 3,464 and Embase: 3,504). The study
selection process is shown in Fig. 1. Nine studies with 2779 cases
and 3484 controls were included in present meta-analysis [4–12].
Four studies had been conducted on Caucasians, one on Asians,
one study on Africans, and three in mixed populations (Caucasians
and African Americans). Six studies were population-based
[4,5,8,10–12]. The others were hospital-based [6,7,9]. In the
hospital-based studies, controls were all selected from among
patients without any sign of any type of cancer. The distribution of
genotypes among controls was consistent with Hardy-Weinberg
equilibrium in all studies except two [8,9]. Two studies collected
information on possible confounding factors like smoking status
[4,6]. In this way, the association between the Ser326Cys
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PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e30309polymorphism and prostate cancer was separately evaluated
among smokers and non-smokers. However, these two studies
only provided the frequency data regarding Ser/Cys+Cys/Cys
and Ser/Ser genotypes. For this reason, only a comparison of Ser/
Cys+Cys/Cys vs. Ser/Ser was conducted.
Meta-analysis
The main results of the current study on the association between
hOGG1 Ser
326Cys polymorphism and the risk of prostate cancer
are shown in Table 2. Overall, no significant association with
prostate cancer was observed using a random effects model in the
comparisons of Ser/Cys to Ser/Ser (OR=1.09, 95% CI: 0.93–
1.28; Pheterogeneity/P=0.047/0.409), Cys/Cys vs. Ser/Ser
(OR=0.91, 95% CI: 0.55–1.52; Pheterogeneity/P=,0.001/0.449),
Ser/Cys+Cys/Cys vs. Ser/Ser (OR=1.12, 95% CI: 0.92–1.37;
Pheterogeneity/P=0.002/0.271), or Cys/Cys vs. Ser/Cys+Ser/Ser
(OR=1.03, 95% CI: 0.66–1.60; Pheterogeneity/P=,0.001/0.913)
in the pooled analysis (Fig. 2). We did not find any significant
results when we stratified the studies by race, country, or source of
the controls.
Genotype information of the Ser
326Cys polymorphism stratified
by smoking status was available in two papers. As shown in Fig. 3,
individuals with Ser/Cys+Cys/Cys genotypes showed more
pronounced increased prostate cancer risk if they were smokers
(OR=2.66, 95% CI=1.5824.47; Pheterogeneity/P=0.365/0.019)
rather than non-smokers (OR=2.18, 95% CI=1.1324.19;
Pheterogeneity/P=0.995/,0.001), relative to those with the Ser/
Ser genotype.
Sensitivity analysis and publication bias
Sensitivity analysis was conducted to assess the influence of each
study on the pooled OR by omission of individual studies. As
shown in Fig. 4, the results suggested that no individual study
would significantly affect the overall OR. Funnel plots and Egger’s
test (Fig. 5) were used to assess publication bias. The results
indicated that there was no evidence of publication bias (t=2.08,
P=0.076 for Ser/Cys vs. Ser/Ser).
Discussion
The potential role of hOGG1 Ser
326Cys polymorphism as a
determinant of prostate cancer risk was investigated in a sample of
6263 subjects from nine published case-control studies. However,
no significant association was found under any genetic model in
the overall analysis. Ever since the hOGG1 Ser
326Cys polymor-
phism was found to occur frequently in human populations,
studies on this polymorphism and the risk of cancer have been
conducted and published. Xu et al. first found this polymorphism
to be associated with the risk of prostate cancer in a Caucasian
population in 2002 [5]. After that, several investigators duplicated
his work in different populations. However, the results remained
confusing, even within the same population. While we were
preparing the present study, a meta-analysis for this same
polymorphism was published by Zhang et al. Their study included
8 papers with 2584 cases and 3234 controls, and they found an
association between hOGG1 Ser
326Cys polymorphism and
prostate cancer in an African-Caucasian-mixed population. In
the current study, we retrieved 9 papers with more subjects and we
also stratified the analyses not only by race but also by country,
source of controls, and smoking status. We found that the Cys
326
allele was associated with a more pronounced increased risk of
prostate cancer in smokers than in non-smokers.
HOGG1 is a key protein involved in base excision repair. It
recognizes and excises lesions from oligodeoxynucleotides with
DNA damage. Recently, studies have suggested that the hOGG1
Cys
326 allele may be associated with an increased risk and severity
of many types of cancer [13]. These results are likely to support the
hypothesis that a minimally active hOGG1*Cys
326 allozyme lacks
the ability to repair the DNA damage induced by environmental
chemicals in carcinogenesis. However, the exact repair function
associated with this polymorphism remains unclear. Kohno et al.
observed that the Cys
326 allele was less capable of complementing
a repair-deficient strain than the Ser
326 allele, while Dherin et al.
found no significant differences in hOGG1 protein enzymatic
activity in vitro [3,14]. Janssen et al. found that DNA repair
activity of hOGG1 in lymphocytes was not dependent on the
Figure 1. Included and excluded studies.
doi:10.1371/journal.pone.0030309.g001
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326Cys polymorphism [15]. Our results showed that the
hOGG1 Cys
326 allele was not associated with the risk of prostate
cancer, confirming that the enzymatic activity of hOGG1 might
not be determined by Ser
326Cys polymorphism alone. Rather, it is
possible that other confounding factors might interact with this
polymorphism in the process of DNA repair.
Although cigarette smoking has been found to be involved in
many cancers and is one of the leading causes of cancer-related
death, its role in prostate cancer remains ill-defined [16]. Recently,
a meta-analysis of 24 prospective cohort studies found smoking to
be associated with higher risk of developing and dying of prostate
cancer [17]. Ngo et al. also found that smoking not only
independently predicted greater tumor volumes and higher grades
in prostate cancer but also a greater risk of biochemical recurrence
after radical prostatectomy [18]. Moreover, smoking was found to
have a destructive effect on DNA [19]. In the present study, gene-
environment interaction was also investigated between hOGG1
Ser
326Cys polymorphism, cigarette smoking, and risk of prostate
cancer. We found that the risk effect of Ser/Cys+Cys/Cys
genotypes was more pronounced among smokers than among
non-smokers. The powers of the subtype analyses were 0.60 in the
non-smoker group and 0.95 in the smoker group, suggesting an
interaction between the hOGG1 polymorphism and smoking with
respect to prostate cancer. Such an interaction is reasonable
Figure 3. Forest plot of prostate cancer risk associated with hOGG1 polymorphism stratified by smoking status. The squares and
horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond
represents the summary OR and 95% CI.
doi:10.1371/journal.pone.0030309.g003
Figure 2. Forest plot of prostate cancer risk associated with hOGG1 polymorphism stratified by race. The squares and horizontal lines
correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the
summary OR and 95% CI.
doi:10.1371/journal.pone.0030309.g002
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reactive oxygen species and DNA adducts that can be caused by
from cigarette smoking. The Cys326 allele has been reported to be
associated with decreased DNA repair activity. For this reason this
allele was thought to be a risk factor for smokers.
The current study has some shortcomings that should be
addressed. First, the U.S., Canadian, and Australian populations
were classified as Caucasian. However, populations in these areas
consist both of indigenous peoples and many types of immigrants,
and not all of the studies stated the ancestries of their participants
clearly. Second, the controls were not uniform either. In hospital-
based studies, most of the controls were BPH patients. Some
individuals in the control group might be likely to develop cancer
in subsequent years, even if they showed no clinical symptoms at
the time of investigation. Misclassification bias can cause deviated
genotype distribution in the controls. In spite of these, the present
meta-analysis also had some advantages over previous studies. For
the first time, we conducted a meta-analysis on hOGG1
polymorphism on prostate cancer susceptibility while considering
possible confounding factors, such as smoking status, by polling the
results of all published independent studies. The statistical power
of the analysis is greater than that of any single study, although it
remains relatively small. The quality of studies included in our
meta-analysis was satisfactory and perfectly met our inclusion
criteria.
In conclusion, our meta-analysis demonstrates that hOGG1
Ser
326Cys polymorphism is a risk factor for prostate cancer in
smokers. Further studies are needed to confirm the relationship.
Figure 5. Begg’s funnel plot for publication bias testing. Each point represents a separate study for the indicated association. Log[OR], natural
logarithm of OR. Horizontal line, mean magnitude of the effect.
doi:10.1371/journal.pone.0030309.g005
Figure 4. Sensitivity analysis conducted to assess the influence of each study on the pooled OR by individual studies omission.
doi:10.1371/journal.pone.0030309.g004
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standing of the association between hOGG1 polymorphism and
the risk of prostate cancer with respect to gene-gene and gene-
environment interactions.
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